

Publications:

- Kundu, N., Brekman, A., Kim, J. Y., Xiao, G., Gao, C., and Bargonetti, J. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway, *Oncotarget* May 24, 2017. PMID: 28615518
- Qiu WG, Polotskaia A, Xiao G, Di L, Zhao Y, Hu W, Philip J, Hendrickson RC, Bargonetti J. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. *NPJ Breast Cancer* 2017 Feb; 3. pii: 1. doi: 10.1038/s41523-016-0001-7 PMID: 28232952
- Shtraizent N, Matsui H, Polotskaia A, Bargonetti J. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. *Int J Environ Res Public Health*. 2015 Dec 22;13(1) . pii: E22. doi: 10.3390/ijerph13010022. PMID: 2670366
- Rosso M, Polotskaia A, Bargonetti J. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. *Oncotarget*. 2015 Oct 27;6(33):34573-91. doi: 10.18632/oncotarget.5312. PMID: 26416444
- Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C. Mutant p53 cooperates with SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. *Genes Dev*. 2015 Jun 15;29(12):1298-315. doi: 10.1101/gad.263202.115. Epub 2015 Jun 16. PMID: 26080815

- Polotskaia, A., Xiao, G., Reynoso, K., Hendrickson, R., Martin, C., Qui, W. and J. Bargonetti. Proteome-wide Analysis of Mutant p53 Targets in Breast Cancer Identifies New Levels of Gain-of-Function that Influence PARP, PCNA and MCM4. (2015) *Proc Natl Acad Sci U S A*.;112(11):E1220-9.
- Xiao, G., Kue, P., Bhosle and J. Bargonetti. Decarbamoyl Mitomycin C (DMC) Activates p53-independent Ataxia Telangiectasia and Rad3 Related Protein (ATR) Chromatin Eviction. (2015) *Cell Cycle* Epub ahead of print Jan 7. PMID: 25565400
- Shi, M., Shtraizent, N., Polotskaia, A., Bargonetti, J. H. Matsui. Impedimetric Detection of Mutant p53 Biomarker-Driven Metastatic Breast Cancers under Hyposmotic Pressure. (2014) *PloS One* Jan 7;9(6):e99351
- Hoffman S., Martin, D., Melendez A. and J. Bargonetti C. elegans p53 and Beclin 1 are involved in DNA repair. (2014) *PloS One* Feb 20;9(2):e88828.
- Okoro D., Arva N., Gao, C., Polotskaia A., Puente, C., Rosso, M., and J. Bargonetti. Endogenous Human MDM2-C is Highly Expressed in Human Cancers and Functions as a p53-independent Growth Activator. (2013) *PloS One* Oct 11;8(10):e77643.
- Catalina-Rodriguez, O., Preet, A., Kolukula, V., Furth, P., Albanese, C, Bargonetti, J. and M.L. Avantaggiati. Dietary regulation of p53 mutant levels influences tumorigenesis. (2012) *Cell Cycle*. 2012 Nov 14;11(23)
- Polotskaia, A., Krett, N., Shanmugam, M., Gamss, S., Rosen, S., and Bargonetti J. 8-Aminoadenosine activates p53-independent cell death of metastatic breast cancers. (2012)

Molecular Cancer Therapeutics.

- Okoro D., Rosso M., and J. Bargonetti. Splicing up Mdm2 for Cancer Proteome Diversity. *Genes & Cancer August 2012.*□

- Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerod, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., Bissell, M. J., Osborne, T. F., Tian, B., Lowe, S. W., Silva, J. M., Borrensen-Dale, A.-L., J., L. A., Bargonetti, J., and Prives, C. (2012) Mutant p53 Disrupts Mammary Acinar Morphogenesis via the Mevalonate Pathway, *Cell* 148 (1-2):244-58. "Success in Molecular Genetics: The Pink Flower" in *Voices of Black American Pioneers*, edited by Vernon Farmer, Greenwood Publishing Group, Westport, Connecticut (2012).
- Brekman, A., Singh K.E., Polotskaia A., Kundu N. and Bargonetti J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. (2011) *Breast Cancer Res.* 13 (1):R3
- Boamah, E.K., Brekman, A., Tomasz, M., Myeku, N., Figueiredo-Pereira, M., Hunter, S., Meyer, J. Bhosle, R.C. and Bargonetti, J. DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of Checkpoint Protein 1. (2010) *Chem. Res. Toxicol.* 19 (23): 1151-62
- Bargonetti, J., Champeil E. and Tomasz, M. Differential Toxicity of DNA Adducts of Mitomycin C. (2010) *Invited Review Journal of Nucleic Acids.* Jul 29;2010. pii: 698960
- Paz, M.M., Ladwa, S., Champell, E., Liu, Y., Rockwell, S. Boamah, E.K., Bargonetti, J., Callahan, J., Roach, J., and Tomasz, M. Mapping DNA Adducts of Mitomycin and Decarbamoyl Mitomycin C in cell Lines Using Liquid Chromatography/ Electrospray Tandem Mass Spectrometry. (2008) *Chem. Res. Toxicol.*, 21(12): 2370-2378.
- Arva, N., Talbott, K., Okoro, D., Brekman, A., Qiu, W., and Bargonetti, J. Disruption of the p53-Mdm2 Complex by Nutlin-3 Reveals Different Cancer Cell Phenotypes. (2008) *Ethnicity and Disease*, 18(2 Suppl 2):S2-1-8.
- Boamah EK, White DE, Talbott KE, Arva NC, Berman D, Tomasz M, Bargonetti J. Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways. *ACS Chem Biol.* 2007 Jun 15;2(6):399-407. Epub 2007 May 25.
- White DE, Talbott KE, Arva NC, Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. *Cancer Res.* 2006 Apr 1;66(7):3463-70.
- Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. *Oncogene.* 2006 Nov 23;25(55):7305-10. Epub 2006 Jun 19

- Arva, N.C., Gopen, T.R., Talbott, K.E., Campbell, L.E., Chicas, A., White, D.E., Bond, G., Levine, A. and J. Bargonetti (2005) A chromatin associated and transcriptionally inactive p53-mdm2 complex occurs in mdm2 SNP309 homozygous cells. *J. Biol. Chem.* 280(29):26776-87
- Bond, G.L., W. Hu, E.E. Bond, H. Robins, F. Bartel, H. Taubert, P. Wuerl, K. Onel, L. Yip, S. Hwang, L.C. Strong, N.C. Arva, J. Bargonetti, G. Lozano, and A.J. Levine (2004) A Single Nucleotide Polymorphism in the Mdm2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. *Cell* 119:591-602.

- Abbas, T., D. White, L.Hui, .D.A., Foster and J. Bargonetti (2004) Inhibition of p53 transcription by down-regulation of protein kinase C delta. *Journal of Biological Chemistry* 279 (11):9970-9977
- Hui, L., Abbas, T., Bargonetti, J., and D.A. Foster. (2004). Phospholipase D Elevates the Level of MDM2 and Suppresses DNA Damage-Induced Increases in p53. *Mol. Cell Biology* (24): 5677-5686.
- Molina, M. P., C. Cain, and J. Bargonetti (2003) In Vivo footprinting and DNA Affinity Chromatography for Analysis of p53 DNA Binding Ability. *Methods in Molecular Biology* 234:151-70
- Abbas, T., M. Olivier, J. Lopez,, S. Houser, G. Xiao, G. S. Kumar, M. Tomasz, and J. Bargonetti (2002). Differential activation of p53 by the various adducts of Mitomycin C. *Journal of Biological Chemistry* 277(43):40513-9.
- Bargonetti, J. and J.J. Manfredi. (2002). Multiple roles of the tumor suppressor p53. *Curr. Opin. Oncology*. 14:86-91.
- Houser, S., S.Koshlatyi , T. Lu , T. Gopen, and J. Bargonetti (2001). Camptothecin and Zeocin Can Differentially Increase p53 Levels During all Cell Cycle Stages. *Biochem Biophys Res Commun*. 289:998-1009.
- Chicas, A., P. Molina, and J. Bargonetti (2000). Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. *Biochem Biophys Res Commun*. 279:383-390.
- Xiao, G., A. Chicas, M. Olivier, Y. Taya, S. Tyagi, F.R. Kramer and J. Bargonetti, (2000). p53 requires a damage signal to activate gadd45. *Cancer Research* 60: 1711-1719.
- Boydston-White, S., T. Gopen, S. Houser, J. Bargonetti and M. Diem, (1999). Infrared spectroscopy of human tissue: V. Infrared Spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. *Biospectroscopy* 5: 219-227.
- Xiao, G., D. White, and J. Bargonetti (1998). p53 binds to a constitutively nucleosome free region of the mdm2 gene. *Oncogene* 16:1171-1181.
- Bargonetti, J., A. Chicas, D. White, and C. Prives (1997). p53 represses Sp1 DNA Binding and HIV-LTR directed transcription. *Cellular & Molecular Biology* 43:935-949.
- Chen, X., J. Bargonetti, and C. Prives, (1995). p53, through p 21 (WAF1/CIP1), induces cyclin D1 synthesis. *Cancer Research* 55:4257-4263.
- Prives, C., J. Bargonetti, G. Farmer, E. Ferrari, P. Friedlander, U. Hubsher, L. Jayaraman, N. Pavletich, and Y. Wang, (1994). The DNA binding properties of the p53 tumor suppressor protein. *CSHS on Quan. Bio. LIX*:207-213.
- Bargonetti, J., J.J. Manfredi, X. Chen, D.R. Marshak, and C. Prives, (1993). A proteolytic fragment from the central region of p53 has marked sequence-specific binding activity when generated from wild-type but not from oncogenic mutant p53 protein. *Genes and Dev*. 7:2565-2574.
- Bargonetti, J., P.Z. Wang, and R.P. Novick, (1993). Measurement of gene expression by translational coupling: effect of copy mutations on pT181 initiator synthesis. *EMBO* 12:3659-3667.
- Friedman, P.N., X. Chen, J. Bargonetti, and C. Prives, (1993). The p53 protein is an unusually shaped tetramer that binds directly to DNA. *Proc. Natl. Acad. Sci. USA*. 90:3319-3323.
- Bargonetti, J., I. Reynisdottir, P.N. Friedman, and C. Prives, (1992). Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. *Genes and Dev*. 6:1886-1898.

Full List of Publications

Last Updated Tuesday, 14 November 2017 21:51

- Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives, (1992). Wild-type p53 activates transcription in vitro. *Nature* 358:83-86.
- Zambetti, G.P., J. Bargonetti, K. Walker, C. Prives, and A.J. Levine, (1992). Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. *Genes and Dev.* 6:1143-1152.
- Prives, C., J. Bargonetti, P.N. Friedman, J.J. Manfredi, and E.H. Wang, (1991). Functional consequences of the interactions of the p53 tumor suppressor protein and SV40 large tumor antigen. *CSHS on Quan. Bio . LVL:227-235.*
- Bargonetti, J., P.N. Friedman, S.E. Kern, B. Vogelstein, and C. Prives, (1991). Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. *Cell* 65:1083-1091.